 |
PDBsum entry 5i9u
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Chemical proteomics and structural biology define epha2 inhibition by clinical kinase drugs.
|
 |
|
Authors
|
 |
S.Heinzlmeir,
D.Kudlinzki,
S.Sreeramulu,
S.Klaeger,
S.L.Gande,
V.Linhard,
M.Wilhelm,
H.Qiao,
D.Helm,
B.Ruprecht,
K.Saxena,
G.Médard,
H.Schwalbe,
B.Kuster.
|
 |
|
Ref.
|
 |
Acs Chem Biol, 2016,
11,
3400-3411.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
No abstract given.
|
 |
|
Secondary reference #1
|
 |
|
Title
|
 |
Expression and purification of epha2 tyrosine kinase domain for crystallographic and nmr studies.
|
 |
|
Authors
|
 |
S.L.Gande,
K.Saxena,
S.Sreeramulu,
V.Linhard,
D.Kudlinzki,
S.Heinzlmeir,
A.J.Reichert,
A.Skerra,
B.Kuster,
H.Schwalbe.
|
 |
|
Ref.
|
 |
Chembiochem, 2016,
17,
2257-2263.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
|
 |
|
|
|
|
 |